Novo Holdings leads Breye Therapeutics’ EUR 67.5 million oversubscribed Series A

Breye Therapeutics raised a EUR 67.5 million oversubscribed Series A co-led by Novo Holdings with Mission BioCapital. Proceeds support a Phase II trial of danegaptide in non-proliferative diabetic retinopathy starting in 2027 and additional retinal-disease pipeline work.